These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24460706)

  • 1. Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.
    Dabisch I; Dethling J; Dintsios CM; Drechsler M; Kalanovic D; Kaskel P; Langer F; Ruof J; Ruppert T; Wirth D
    Health Econ Rev; 2014 Jan; 4(1):2. PubMed ID: 24460706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
    Staab T; Isbary G; Amelung VE; Ruof J
    BMC Health Serv Res; 2016 Nov; 16(1):651. PubMed ID: 27842592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
    Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
    Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.
    Ruof J; Knoerzer D; Dünne AA; Dintsios CM; Staab T; Schwartz FW
    Health Policy; 2014 Nov; 118(2):242-54. PubMed ID: 25194474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Involvement of scientific societies in early benefit assessment: Simulated participation or valuable additional input?].
    Bleß HH; Seidlitz C; Ohlmeier C; de Millas C
    Z Evid Fortbild Qual Gesundhwes; 2018 Feb; 130():49-57. PubMed ID: 29103831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
    Ruof J; Flückiger O; Andre N
    Drugs R D; 2015 Sep; 15(3):221-6. PubMed ID: 26286202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Challenges for clinical trials in oncology within the scope of early benefit assessment of drugs].
    Lange S
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(6):417-30. PubMed ID: 26474646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
    Fischer KE; Stargardt T
    Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EUPATI and Patients in Medicines Research and Development: Guidance for Patient Involvement in Ethical Review of Clinical Trials.
    Klingmann I; Heckenberg A; Warner K; Haerry D; Hunter A; May M; See W
    Front Med (Lausanne); 2018; 5():251. PubMed ID: 30246010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data.
    Peinemann F; Labeit A
    J Evid Based Med; 2019 Feb; 12(1):9-15. PubMed ID: 30701688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
    Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
    Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated, cross-sectoral psycho-oncology (isPO): a new form of care for newly diagnosed cancer patients in Germany.
    Kusch M; Labouvie H; Schiewer V; Talalaev N; Cwik JC; Bussmann S; Vaganian L; Gerlach AL; Dresen A; Cecon N; Salm S; Krieger T; Pfaff H; Lemmen C; Derendorf L; Stock S; Samel C; Hagemeier A; Hellmich M; Leicher B; Hültenschmidt G; Swoboda J; Haas P; Arning A; Göttel A; Schwickerath K; Graeven U; Houwaart S; Kerek-Bodden H; Krebs S; Muth C; Hecker C; Reiser M; Mauch C; Benner J; Schmidt G; Karlowsky C; Vimalanandan G; Matyschik L; Galonska L; Francke A; Osborne K; Nestle U; Bäumer M; Schmitz K; Wolf J; Hallek M
    BMC Health Serv Res; 2022 Apr; 22(1):543. PubMed ID: 35459202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
    Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
    Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Adjusted and Unadjusted Indirect Comparison Methods in Benefit Assessment. A Simulation Study for Time-to-event Endpoints.
    Kühnast S; Schiffner-Rohe J; Rahnenführer J; Leverkus F
    Methods Inf Med; 2017 May; 56(3):261-267. PubMed ID: 28361159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.